Transfer of Cholesterol and Other Lipids From a Lipid Nanoemulsion to High-density Lipoprotein in Heart Transplant Patients

Journal of Heart and Lung Transplantation

Volumn 28, Issue 10, 2009, Pages 1075-1080

  Puk, Camila Góes ^a   Bocchi, Edimar Alcides ^a   Lo Prete, Ana Cristina ^a   Ferreira, Silvia Moreira Ayub ^a   Stolf, Noedir Antônio Groppo ^a   Maranhão, Raul Cavalcante ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; ARYLDIALKYLPHOSPHATASE 1; AZATHIOPRINE; CHOLESTEROL; CHOLESTEROL ESTER; CYCLOSPORIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PHOSPHOLIPID; PREDNISONE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HEART TRANSPLANTATION; HUMAN; LIPID BLOOD LEVEL; LIPID TRANSPORT; MALE; NANOEMULSION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70349243517     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.05.024     Document Type: Article

References (39)

1. Brunner-La Rocca H.P., Scheneider J., et al. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation 65 (1998) 538-543
2. Schmid C., Kerhet H.A., Deng M., et al. Graft vascular disease after heart transplantation. Eur Heart J 18 (1997) 554-557
3. Ramzy D., Rao V., Brahm J., et al. Cardiac allograft vasculopathy: a review. Can J Surg 48 (2005) 319-327
4. Bilodeau M., Fitchet D.H., Guerraty A., et al. Dyslipoproteinemias after heart and heart-lung transplantation: potential relation to accelerated graft arteriosclerosis. J Heart Lung Transplant 8 (1989) 454-459
5. Park J.W., Merz M., Braun P., et al. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation. J Heart Lung Transplant 15 (1996) 572-579
6. Perrault L.P., Mahlberg F., Breugnot C., et al. Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation. Arterioscler Thromb Vasc Biol 20 (2000) 728-736
7. Akhlaghi F., Jackson C.H., Parameshwar J., et al. Risk factors for the development and progression of dyslipidemia after heart transplantation. Transplantation 73 (2002) 1258-1264
8. Bellotti G., Bocchi E.A., Goiato M.A., et al. Lipid profile changes during the late follow-up after heart transplantation. Arq Bras Cardiol 66 (1996) 263-266
9. Puk C.G., Vinagre C.G., Bocchi E., et al. Plasma kinetics of a cholesterol-rich microemulsion in patients submitted to heart transplantation. Transplantation 78 (2004) 1177-1181
10. Vinagre C.G., Stolf N.A., Bocchi E., et al. Chylomicron metabolism in patients submitted to cardiac transplantation. Transplantation 69 (2000) 532-537
11. Sviridov D., Chin-Dusting J., Nestel P., et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 81 (2006) 361-366
12. Stamler J.S., Vaughan D.E., Rudd M.A., et al. Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 62 (1988) 1268-1272
13. Badiou S., Perez V., Dupuy A.M., et al. High prevalence of small dense LDL as an underestimated component of heart transplantation-induced dyslipidemia: potential role in graft coronary vasculopathy?. Transplant Proc 37 (2005) 2877-2878
14. Asztalos B.F., and Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 91 suppl (2003) 12E-17
15. Wang M., and Briggs M.R. HDL: the metabolism, function, and therapeutic importance. Chem Rev 104 (2004) 119-137
16. Schaefer E.J., Zech L.A., Jenkins L.L., et al. Human apolipoprotein A-I and A-II metabolism. J Lipid Res 23 (1982) 850-862
17. von Eckardstein A., Nofer J.R., and Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21 (2001) 13-27
18. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221
19. Mahley R.W., Huang Y., and Weisgraber K.H. Putting cholesterol in its place: apo E and reverse cholesterol transport. J Clin Invest 116 (2006) 1126-1129
20. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 47 suppl (2006) C7-C12
21. Sviridov D., and Nestel P. Dynamics of reverse cholesterol transport; protection against atherosclerosis. Atherosclerosis 161 (2002) 245-254
22. Superko H.R., Haskell W.L., and Di Ricco C.D. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am J Cardiol 66 (1990) 131-134
23. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
24. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
25. Lima E., and Maranhão R.C. Rapid, simple laser-light scattering method for HDL particle size in whole plasma. Clin Chem 50 (2004) 1086-1088
26. Maranhão R.C., Cesar T.B., Pedroso-Mariani S.R., et al. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 28 (1993) 691-696
27. Guidance for Industry. Bioanalytical method validation (2001), Silver Spring, MD, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM) FDA
28. Stein O., and Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178 (2005) 217-230
29. O'Brien K.D., Vuletic S., McDonald T.O., et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 108 (2003) 270-274
30. Lewis G.F. Determinants of plasma HDL concentrations and reverse cholesterol. Curr Opin Cardiol 21 (2006) 345-352
31. Giribela A.H., Melo N.R., Latrilha M.C., et al. HDL concentration, lipid transfer to HDL, and HDL size in normolipidemic nonobese menopausal women. Int J Gynaecol Obstet 104 (2009) 117-120
32. Rocha MP, Maranhão RC, Seydell TM, et al. Metabolism of triglyceride-rich lipoproteins and transfer of lipids to high-density lipoprotein in young obese and normal weight patients with polycystic ovary syndrome. Fertil Steril (in press).
33. Santos R.D., Hueb W., Oliveira A.A., et al. Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. J Lipid Res 44 (2003) 464-469
34. Couto R.D., Dallan L.A., Lisboa L.A., et al. Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis. Lipids 42 (2007) 411-418
35. Azevedo C.A., Lo Prete A.C., Puk C., et al. Capacity of the high density lipoprotein to receive lipids in age groups: a study using an artificial nanoemulsion. Atherosclerosis 9 (2008) 24
36. Kotake H., Sekikama A., Yoshihisa T., et al. Effect of HMG-CoA redutase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups. J Atheroscler Thromb 9 (2002) 207-212
37. White M., White M., Haddad H., et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 24 (2005) 798-809
38. Costa L.G., Vitalone A., Cole T.B., et al. Modulation of paraoxonase (pon1) activity. Biochem Pharmacol 69 (2005) 541-550
39. Tall A.R., Laurent I.C., and Wang T. The failure of Torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260